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Introduction. The clinical feasibility of noninvasive imaging of interstitial alterations after
myocardial infarction (MI) was assessed using a technetium-99m-labeled RGD imaging peptide
(RIP). In experimental studies, RIP has been shown to target integrins associated with collagen-
producing myoﬁbroblasts (MFB).
Methods and Results. Ten patients underwent myocardial perfusion imaging (MPI) within
the ﬁrst week after MI. At 3 and 8 weeks after MI, RIP was administered intravenously and
SPECT images acquired for interstitial imaging. RIP imaging was compared to initial MPI and
to the extent of scar formation deﬁned by late gadolinium-enhanced (LGE) cardiac magnetic
resonance (CMR) imaging 1 year after MI. RIP uptake was observed in 7 of the 10 patients at
both 3 and 8 weeks. Although, RIP uptake corresponded to areas of perfusion defects, it usually
extended beyond the infarct zone to a variable extent; 2 of 7 patients showed tracer uptake
throughout myocardium. In all positive cases, RIP uptake was similar to the extent of scar
observed at 1 year by LGE-CMR imaging.
Conclusion. This study demonstrates that RGD-based imaging early after MI may predict
the eventual extent of scar formation, which often exceeds initial MPI deﬁcit but colocalizes
with LGE in CMR imaging performed subsequently. (J Nucl Cardiol 2010;17:1065–72.)
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INTRODUCTION
The process of ventricular remodeling after acute
myocardial infarction (MI) plays an important role in
predisposition to heart failure (HF).
1 Current morphol-
ogy-based imaging modalities, such as cardiovascular
magnetic resonance (CMR) imaging and echocardiog-
raphy, provide excellent information about left
ventricular (LV) chamber enlargement and dysfunction
after MI.
2,3 However, these changes represent delayed
and only partially reversible consequences of remodel-
ing.
4,5 As such, clinical recognition of changes
preceding clinically manifest ventricular remodeling
may be of paramount importance for prevention of
HF.
6,7 Remodeling is histopathologically characterized
in addition to myocardial hypertrophy, by replacement
and interstitial ﬁbrosis, and may constitute worthy target
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1065for identiﬁcation of patients at high risk of developing
HF and allow appropriate intervention.
8 Several candi-
date biological processes have been targeted for
molecular imaging of cardiac remodeling.
9 The upreg-
ulation of the myocardial renin-angiotensin axis (RAS)
has been proposed as potential target for identiﬁcation of
the likelihood of myocardial ﬁbrosis.
10 Radiolabeled
benzoyl lisinopril and losartan have been employed in
pre-clinical studies for the noninvasive detection of
intracellular angiotensin-converting enzyme and cell-
membrane angiotensin II type 1 receptors, respectively,
with the premise that characterization of subcellular
changes should precede morphological evidence of
remodeling.
11,12
It has also been recently demonstrated that an RGD
imaging peptide (RIP) successfully targeted proliferating
myoﬁbroblasts (MFB) in an experimental model of post-
MI heart failure.
13 Although RIP-like molecules have
been traditionally employed to target avb3 integrin
expression associated with neoangiogenesis in
tumors,
14,15 the experimental studies have revealed its
localization ina-smoothmuscle actin bearing MFBinthe
healingmyocardium in[2-week-oldMI.Inexperimental
studies,RIPuptakemaximizesat2-4 weeks post-MI,and
reduces substantially by 12 weeks. Use of antagonists of
the RAS axis including ACE-inhibitors and angiotensin
receptor blockers reduce the RIP uptake in post-MI ani-
mals, particularly in the remote myocardial regions. RIP
uptake in these studies correlated with the extent of MFB
inﬁltration and the magnitude of new collagen ﬁber
deposition; tracer uptake also correlated with echocar-
diographic parameters of ventricular remodeling.
13,16
In the present proof of concept study to explore
clinical applicability of RIP, we employed a serial,
3- and 8-week imaging study with
99mTc-labeled RIP in
patients following their ﬁrst MI. The 3-week time point
was chosen based on the abovementioned animal stud-
ies, which demonstrated a peak in tracer uptake between
2-4 weeks and a reduction by 6-12 weeks. The 8-week
time point was chosen to see whether a similar pattern
could be seen in patients. Subsequently, we compared
RIP uptake to the infarct size by pre-discharge myo-
cardial perfusion imaging and to the extent of ﬁbrosis
veriﬁed by late gadolinium-enhanced (LGE) CMR
imaging 1-year later. Echocardiographic parameters of
ventricular remodeling were obtained at baseline and
serially during follow up.
METHODS
Twelve consecutive patients presenting with their ﬁrst
acute MI were prospectively enrolled between October 2005
and January 2006. No patient had a known history of coronary
disease. All underwent coronary angiography and percutaneous
coronary intervention (PCI) upon arrival in hospital. All
patients were 18 years or older, and either male or post-
menopausal/surgically sterile/nonpregnant females. Patients
participating in other investigational drug studies within
30 days before this study or scheduled for one during follow-up
of this study were excluded. Patients were also excluded if they
were scheduled for a coronary artery bypass surgery within
30 days ofstudy entry.The studycomplies with the Declaration
of Helsinki and was approved by the institutional review board
of the Maastricht University and Hospital. All patients provided
informed consent in writing before enrollment.
A complete set of study data was available in 10 patients:
entry, 3 and 8 weeks, and 6 and 12 months follow-up (Fig-
ure 1). Two patients were excluded before imaging: one due to
a major gastric bleed and the other to coronary bypass surgery.
At all time points, blood was collected for laboratory investi-
gations, including pro-BNP, and antibodies against RIP (to
exclude evidence of a possible immune response). Echocar-
diography was performed (iE33 ultrasound system, Philips
Medical Systems, Andover, Massachusetts) at all follow-up
8 weeks
99mTc-RIP
imaging
3 weeks Admission 
following MI
Consent 
Discharge
MPI
6 months 12 months
Echo Echo Echo Echo Echo
99mTc-RIP
imaging
CMR
Figure 1. Schematic presentation of the clinical study protocol. Patients were enrolled during
hospitalization for their ﬁrst MI. All underwent myocardial perfusion imaging (MPI) before
discharge from hospital. All patients were brought back for
99mTc-RIP scintigraphy at 3 and 8 weeks
after MI. Echocardiography was performed at baseline, 3 and 8 weeks, and 6 and 12 months.
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in the apical 4- and parasternal 2-chamber views. Nomencla-
ture of LV segments and measurements of LV dimensions are
based on the recommendations of the American Society of
Echocardiography.
17 All patients were on aspirin, anti-platelet
agents (aspirin and clopidogrel), statins, beta blockers and
either ACE-inhibitor or ARB. Patients #1 and #9 also received
a selective aldosterone receptor antagonist.
Myocardial Perfusion Imaging
Just before discharge from the hospital, all patients
underwent (stress-rest) myocardial perfusion imaging (MPI)
using a technetium-99m Sestamibi SPECT to deﬁne the extent
of MI. For stress and rest MPI, 280 and 550 MBq (7.6 and
14.9 mCi) of MIBI was administered, respectively, and
imaging was performed 1 hour later. The SPECT studies were
performed with a triple-head gamma camera (Siemens Multi-
SPECT-3, Hoffman Estates, IL, USA) as previously
described.
18 The effective radiation dose was 2.2 mSv from
the stress, and 4.5 mSv from the rest MPI.
99mTechnetium-RIP Imaging
RIP, a bi-cyclic peptide with an RGD motif, NC100692,
was kindly supplied by GE Healthcare (Oslo, Norway). RIP
SPECT imaging studies were performed at 1 and 2 hours after
intravenous radiotracer administration, 3 and 8 weeks after
MI; patients received not less than 780 MBq and not more than
949 MBq of radioactivity. The effective radiation dose from
99mTc-RIP is .008 mSv/MBq or a total of 7.8 mSv for a single
injection of 1 GBq.
LGE-CMR Imaging
All patients underwent CMR imaging 12 ± 1.4 months
after MI, using a 1.5T scanner (Intera, Philips Medical Sys-
tems, Best, the Netherlands). ECG-gated cine imaging was
performed for evaluation of wall motion abnormalities, LV
volumes, ejection fraction and mass, using a multi-phase,
steady-state free precession sequence (bFFE). Continuous
short axis images as well as single slices in 2- and 4-chamber
and LV outﬂow tract view were obtained (TE 1.9 ms, TR
3.8 ms, ﬂip angle 50, slice thickness 6 mm, FOV 35 mm,
scan matrix 256 9 256). LGE images were acquired approx-
imately 10 minutes after injection of .2 mmol/kg Gd-DTPA,
for infarct localization and infarct sizing, using a 3D
T1-weighted inversion-recovery gradient-echo technique
(continuous short axis, 2- and 4-chamber views, TE 1.3 ms,
TR 4.2 ms, slice thickness 10 mm, ﬂip angle 15).
Image Analysis
Reconstruction and image display of all
99mTc-RIP scans
were performed for all subjects, using a GE Healthcare Xeleris
workstation V1.3, by one investigator, to ensure consistency.
Filtered back-projection was then performed with a Hann
pre-ﬁlter (cut-off frequency of .56 cycles per pixel, order 5.0),
a reconstruction ramp ﬁlter, and a Butterworth post-ﬁlter (cut-
off frequency of .52 cycles per pixel, order 5.0). No scatter or
attenuation corrections were applied, but automatic motion
correction was used when excessive movement was observed.
Images were displayed in the CEqual color scale, in short,
vertical, and horizontal axes slice orientations, as well as in
polar plots with the 17-segment model overlay. The SPECT
and SPECT/CMR image overlay was performed using the
biomedical image quantiﬁcation and kinetic modeling software
package PMOD (PMOD Technologies LTD, Adliswil, Swit-
zerland). Superimposition of combined MPI, 3- and 8-week
RIP imaging was performed with automatic co-registration and
alignment of reconstructed images; CMR images were super-
imposed by applying an additional scale correction
necessitated by different resolutions of SPECT and CMR
modalities.
Quantiﬁcation of the area of uptake and total counts
(normalized for injected activity) was recorded and change in
radiotracer uptake in myocardium from 3 to 8 weeks was
calculated (see Table 2). We used a descriptive semi-quanti-
tative SPECT scoring for uptake (localization). Absolute
counts were used in the evaluation of change of uptake
between 3 and 8 weeks and deﬁned as increased, no change, or
decreased (?,=,-). The scoring could reliably be performed
for the anterior wall infarctions and suboptimally in inferior
infarctions, due to scattered hepatic uptake towards the inferior
wall of the heart. Absolute counts from myocardial SPECT
images could not be performed in the absence of attenuation
correction.
CMR images were analyzed using CASS software (Pie-
medical Inc, Maastricht, the Netherlands). End-diastolic and
end-systolic volumes were measured by manual delineation of
endocardial and epicardial borders on continuous cine short
axis images. Wall motion was analyzed visually and graded as
normal, hypokinetic, akinetic, or dyskinetic. Localization,
transmurality and size of infarct (%LV) were determined on
late enhancement images with manual delineation of endo-
cardial and epicardial as well as infarct borders.
RESULTS
Serial RIP Imaging After MI
Clinical characteristics of all patients are provided
in Table 1. Of the 10 patients, 7 demonstrated myocar-
dial RIP uptake both at 3 and 8 weeks; 3 patients
showed no uptake (Figure 2). The difference in RIP
uptake could reliably be calculated in 5 of 7 cases; total
area of uptake increased in 2 patients at 8 weeks, and
remained unchanged in the remaining 3 (see Table 2).
There was a decrease in total counts in the region of
interest in 2 patients, while the area of uptake area
remained unchanged. There was an increase in the total
count in region of interest in 3 of 5 patients, while the
area of uptake increased in only 2 and remained
unchanged in one. Technically, 2-hour post-injection
Journal of Nuclear Cardiology Verjans et al 1067
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No. Sex Age BMI Symptoms Artery Intervention
1 F 39 26.8 VF RCA prox Primary PCI
2 F 49 25.9 AP LAD D1 Primary PCI
3 M 72 23.8 AP LAD mid Primary PCI
4 M 55 22.8 VF LAD prox Primary PCI
5 F 63 27.5 AP LAD prox Primary PCI
6 M 59 32.7 AP LAD prox ? mid Primary PCI
7 F 51 21.9 AP RCA marg Primary PCI
8 M 43 30.0 AP RCA mid Primary PCI
9 M 58 26 AP Cx prox Primary PCI ? Thrombolysis
10 M 44 28 AP RCA mid Primary PCI
All culprit vessels demonstrated 99–100% occlusion except patient #6 (70–90%).
BMI, Body mass index; VF, ventricular ﬁbrillation; AP, angina pectoris; prox, proximal; marg, marginal; PCI, percutaneous coronary
intervention.
Patient 3
RIP 8wk
MPI 3wk
Patient 5 Patient 7
VLA VLA SA SA VLA SA
RIP 3wk
MPI
Figure 2. Stress MPI at discharge and
99mTc-RIP imaging at 3 and 8 weeks post-MI in 3 patients. The left upper panel
demonstrates the short axis (SA) and vertical long axis (VLA) views of perfusion defects delineated by myocardial perfusion
imaging (MPI) in the anterolateral region in patient #3 (red arrows).
99mTc-RIP images at 3 and 8 weeks (rows 2 and 3) show
uptake (blue arrows) corresponding to the infarct and border zone delineated by MPI (red arrows). L denotes liver. The
middle column shows patient #5 with a LAD region perfusion defect in MPI.
99mTc-RIP uptake in SA view extends beyond
the infarct border zone at 3 and 8 weeks (red vs blue arrows). Patient #7 (right panel) is an example of a small RCA infarct
(red arrows) with little or no
99mTc-RIP uptake at 3 and 8 weeks. The last row in all the panels represents fusion images of
3-week
99mTc-RIP and baseline MPI.
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those at 1 hour with higher target-to-background ratios.
Myocardial Perfusion Defects and RIP
Uptake
As expected, myocardial perfusion defects corre-
lated with the angiographic coronary artery involvement
and echocardiographic wall motion abnormality. RIP
uptake corresponded to the perfusion defects in all 7
patients with positive scans (Figure 2). In 5 of these 7
cases, uptake extended beyond the myocardial perfusion
defect. In patients #4 and #5, RIP uptake extended from
the infarct zone into the remote zone, and showed almost
global uptake (Table 2).
RIP Uptake and CMR Imaging
The ﬁnal extent of the scar tissue, as veriﬁed by
LGE-CMR imaging, was established 1 year after MI.
Mean LV mass was 103 ± 23 g and the infarct zone
occupied 19.1 ± 11.6% of the myocardial area. RIP
uptake at 3 and 8 weeks colocalized well in patients
with the CMR-veriﬁed myocardial scar tissue (Fig-
ure 3). One patient with a large antero-apical and small
septal scar by CMR showed colocalization with RIP
uptake in both scar regions (Figure 3).
Evolution of LV Function Over 1 Year
Follow-Up
During follow-up, mean LV ejection fraction
decreased from 51 ± 10% at baseline to 47 ± 8% over
time. LV ejection fraction decreased in 1 year by more
than 10% in 2 patients. Patient #9 suffered from severe
mitral valve regurgitation in a left circumﬂex coronary
artery infarct and ejection fraction decreased from 59%
to 39%. Patient #2 exhibited physical ﬁndings of HF
including dyspnea and progressive shortness of breath
during exercise; LV ejection fraction decreased from
47% to 37%. Pro-BNP decreased in all (except patient
#7) from 95 ± 86 pmol/l at baseline to almost normal
levels 25 ± 14 pmol/l at 12 months (see Table 2). No
antibodies to RIP were detected in any of the patients.
DISCUSSION
Molecular imaging of MFB proliferation, employ-
ing Cy5.5-RIP, has recently been demonstrated as an
indicator of new collagen deposition and myocardial
remodeling in a post-MI mouse model.
13 This study
shows the feasibility of clinical imaging with radiola-
beled RIP in post-MI patients. Radiotracer uptake was
observed in 7 of 10 patients and was predominantly
localized within the infarct and peri-infarct region, but
extended into the remote zones in two cases. Quantiﬁ-
cation of
99mTc-RIP in 5 positive patients at the 3- and
8-week intervals revealed increased extent of uptake in
the myocardium at 8 weeks for 2 patients, whereas the
remaining 3 patients showed no change in uptake at
8-weekswhencomparedto3-weekscans.Intriguingly,the
extent of tracer uptake measured at 3 weeks co-localized
withﬁbroticregions delineatedbyCMRimagingat1 year
after MI, suggesting that the region visualized by RIP
imaging might predict ﬁnal scar formation after MI.
Following cardiomyocyte necrosis and the inﬂamma-
tory process, proliferating myoﬁbroblast and endothelial
cell precursors migrate into the infarct zone replacing
dead tissue with granulation tissue.
19 Concomitantly,
avb3 integrins are upregulated in the infarct region.
20 It
is well recognized that the expression of the b3 integrins
contributes to angiogenesis in the peri-infarct zone as a
part of the remodeling process, and occurs early, peak-
ing about 7 days after MI. In a later stage, the avb3
integrins are associated with ﬁbroblast-like cells, such
as myoﬁbroblast-producing collagens.
13,21 Over time,
collagen ﬁbrils are cross-linked by transglutaminase
activity and myoﬁbroblasts recede, resulting in a
decrease in the integrin availability. Previous animal
work from our lab suggests that uptake of our compound
Cy5.5-labeled-RIP after MI period predominantly iden-
tiﬁes the prevalence of myoﬁbroblasts in the infarct
region.
13 The observation that RIP uptake at 3 weeks co-
localized well with the eventual extent of ﬁbrosis veri-
ﬁed by CMR, suggests that uptake by interstitial cells
precedes localization of the scar subsequently. Some
uptake of the tracer within the regions of angiogenesis
(as observed after MI, hindlimb ischemia and in cancer
employing similar integrin-targeting tracers) cannot be
discounted,
14,15,22,23 we have not observed much angi-
ogenesis in the transmurally scarred regions in our
animal model at least 2 weeks after MI. Both the
observations in the preclinical and the clinical studies
using RIP indicate that uptake of the tracer is linked to
eventual development of myocardial scar.
The number of patients included in this pilot study,
and the variation in extent, density, and localization of
remodeling parameters in the individual patient, makes
it difﬁcult to predict whether RIP imaging would help
identify patients likely to develop LV remodeling.
However, RIP imaging could hypothetically play a role
in personalization of clinical management after MI. The
neurohumoral antagonists are effective in the prevention
of myocardial remodeling and use of them in combi-
nation has resulted in more favorable outcomes.
24,25
Various follow-up studies have demonstrated that many
patients may not receive optimal therapy for various
reasons, and identiﬁcation of patients needing aggressive
Journal of Nuclear Cardiology Verjans et al 1069
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in the cascade of remodeling. It is also possible that
serial interrogation with such imaging may facilitate
optimization. We have recently reported the value of
treatment with neurohumoral antagonists with Cy5.5-
RIP uptake in an animal study, its correlation with
remodeling parameters and the extent of myoﬁbroblastic
proliferation and collagen deposition.
13 We have initi-
ated a larger clinical study to explore the capability of
RIP imaging to evaluate efﬁcacy of anti-ﬁbrotic agents
in post-infarct subjects.
The data presented here should be interpreted with
caution due to a small number of patients. Nonetheless,
the study offers a successful attempt of feasibility of
molecular imaging for the evaluation of interstitial
changes after MI in a clinical setting. Further, discrim-
ination of tracer uptake in the inferior myocardial wall
from liver uptake is a common limitation of SPECT
nuclear imaging studies, and SPECT data are not fully
quantitative. Finally, merging images at such distant
time points might not be fully accurate. These limita-
tions could signiﬁcantly be mitigated by concomitant
morphologic imaging, a strategy planned for our future
study.
This study demonstrates proof of principle for
imaging integrin upregulation in the infarct region in
patients at early time points after MI. Since experi-
mental data suggest that integrin upregulation is
associated with ﬁbroblastic activity (and hence with
collagen deposition) the extent of radiolabeled RIP
uptake may predict cardiac remodeling. The tracer
uptake in this study colocalized with the LGE-CMR-
veriﬁed myocardial ﬁbrosis. Although we have focused
on tracer uptake in the infarct region and surrounding
myocardium, it will be necessary for clinical beneﬁt that
such an agent is able to pick up subtle increases in
myoﬁbroblastic activity in remote myocardium.
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